Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
Aldeyra Therapeutics (Nasdaq: ALDX) has announced a webcast and conference call scheduled for August 8, 2024, at 9:00 a.m. ET to reveal top-line results from the Phase 3 dry eye disease clinical trial of reproxalap. The company, focused on developing therapies for immune-mediated and metabolic diseases, will provide dial-in numbers for domestic and international callers, with a live audio webcast accessible from their website. Aldeyra's pipeline includes RASP modulators for various systemic and retinal diseases, with reproxalap targeting dry eye disease and allergic conjunctivitis, and ADX-2191 for potential treatment of retinitis pigmentosa.
Aldeyra Therapeutics (Nasdaq: ALDX) ha annunciato una conferenza web e una chiamata programmata per l'8 agosto 2024, alle 9:00 ET, per rivelare i risultati preliminari del trial clinico di fase 3 sulla malattia dell'occhio secco con reproxalap. L'azienda, focalizzata sullo sviluppo di terapie per malattie mediate dal sistema immunitario e metaboliche, fornirà numeri di accesso per chiamanti nazionali e internazionali, con una trasmissione audio in diretta accessibile dal loro sito web. Il pipeline di Aldeyra include modulatori RASP per varie malattie sistemiche e retiniche, con reproxalap che mira alla malattia dell'occhio secco e alla congiuntivite allergica, e ADX-2191 per il potenziale trattamento della retinite pigmentosa.
Aldeyra Therapeutics (Nasdaq: ALDX) ha anunciado una transmisión web y una llamada programada para el 8 de agosto de 2024, a las 9:00 a.m. ET, para revelar los resultados preliminares del ensayo clínico de fase 3 sobre la enfermedad del ojo seco con reproxalap. La empresa, que se centra en desarrollar terapias para enfermedades mediadas por el sistema inmunológico y enfermedades metabólicas, proporcionará números de llamada para nacionales e internacionales, con una transmisión de audio en vivo accesible desde su sitio web. El pipeline de Aldeyra incluye moduladores RASP para diversas enfermedades sistémicas y retinianas, siendo reproxalap dirigido a la enfermedad del ojo seco y a la conjuntivitis alérgica, y ADX-2191 para el tratamiento potencial de la retinitis pigmentosa.
Aldeyra Therapeutics (Nasdaq: ALDX)는 2024년 8월 8일 오전 9시 ET에 예정된 웹캐스트 및 컨퍼런스 콜을 발표하였으며, reproxalap의 3상 건성안 질환 임상 시험의 주요 결과를 공개할 예정입니다. 면역 매개 및 대사 질환 치료제 개발에 집중하는 이 회사는 국내 및 국제 발신자를 위한 전화 접속 번호를 제공하며, 자사 웹사이트에서 실시간 오디오 웹캐스트를 이용할 수 있습니다. Aldeyra의 파이프라인에는 다양한 전신 및 망막 질환에 대한 RASP 조절제가 포함되어 있으며, reproxalap은 건성안 질환 및 알레르기 결막염을 목표로 하고 있으며, ADX-2191은 망막색소변성증의 잠재적 치료를 위해 개발되고 있습니다.
Aldeyra Therapeutics (Nasdaq: ALDX) a annoncé un webcast et une conférence téléphonique programmés pour le 8 août 2024 à 9h00 ET, afin de révéler les résultats préliminaires de l'essai clinique de phase 3 sur la maladie de l'œil Sec avec reproxalap. L'entreprise, qui se concentre sur le développement de thérapies pour des maladies médiées par le système immunitaire et métaboliques, fournira des numéros de connexion pour les appelants nationaux et internationaux, avec un webcast audio en direct accessible depuis leur site web. Le pipeline d'Aldeyra comprend des modulateurs RASP pour diverses maladies systémiques et rétiniennes, reproxalap visant la maladie de l'œil sec et la conjonctivite allergique, et ADX-2191 pour le traitement potentiel de la rétinite pigmentaire.
Aldeyra Therapeutics (Nasdaq: ALDX) hat eine Webkonferenz und einen Konferenzanruf für den 8. August 2024 um 9:00 Uhr ET angekündigt, um die Ergebniss des klinischen Phase-3-Tests für trockene Augenkrankheit mit reproxalap zu präsentieren. Das Unternehmen, das sich auf die Entwicklung von Therapien für immunvermittelte und Stoffwechselkrankheiten konzentriert, wird Einwahlnummern für inländische und internationale Anrufer bereitstellen, sowie ein Live-Audio-Webcast, der über ihre Website zugänglich ist. Die Pipeline von Aldeyra umfasst RASP-Modulatoren für verschiedene systemische und Netzhauterkrankungen, wobei reproxalap auf trockene Augenkrankheit und allergische Konjunktivitis abzielt und ADX-2191 zur potenziellen Behandlung von Retinitis pigmentosa gedacht ist.
- Upcoming announcement of Phase 3 clinical trial results for reproxalap in dry eye disease
- Diverse pipeline of RASP modulators for multiple immune-mediated and metabolic diseases
- Late-stage product candidates targeting significant ophthalmic conditions
- None.
The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.
After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807851086/en/
Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
FAQ
When will Aldeyra Therapeutics (ALDX) announce the Phase 3 dry eye disease trial results for reproxalap?
What are the main product candidates in Aldeyra Therapeutics' (ALDX) pipeline?
What is the therapeutic approach of Aldeyra Therapeutics (ALDX)?
How can investors access Aldeyra Therapeutics' (ALDX) upcoming conference call on August 8, 2024?
